KORU Medical Systems, Inc. (KRMD)

Over the past six months, KORU Medical Systems' stock has experienced fluctuations, with an increase of +11.11% over the last six months, but decreases of -29.37% over the last three months and -7.76% in the past month. Key events include EU MDR Certification for its Freedom60 Infusion Pump, a CEO transition, reported +20% Fourth Quarter and Full Year 2025 Revenue Growth, Q4 2025 EPS beating expectations, FDA 510(k) clearance for RYSTIGGO® delivery, expanded development pipeline, and increased price target.

The available information does not explicitly detail demand seasonality. However, the company's focus on providing solutions for chronic illnesses suggests a relatively consistent demand for its products, further indicated by robust demand for immunoglobulin therapy.

KORU Medical Systems, Inc. specializes in subcutaneous infusion solutions within the Healthcare sector, focusing on Medical Instruments & Equipment. Its major products include the FREEDOM infusion systems, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing, designed for therapies for chronic illnesses like PIDD, CIDP, SIDD, and PNH.

KORU Medical Systems is headquartered in Mahwah, New Jersey, and has a geographic footprint across the United States and internationally, with a focus on international core growth. The majority of its revenue is derived from its Domestic Core business, including sales of its syringe drivers, tubing, and needles.

KORU Medical Systems emphasizes a patient-centric focus and responsive problem-solving. Recent positive developments, such as EU MDR Certification and FDA 510(k) clearance, contribute positively to its brand image. The rebranding in March 2022 aimed to reflect a more patient-centric mission.

KORU Medical Systems has a significant institutional presence, with 100 institutional owners and shareholders holding 20,655,841 shares. Major institutional owners include First Light Asset Management, LLC, Topline Capital Management, LLC, and BlackRock, Inc. Individual and insider ownership accounts for 6.93% of shares, the general public holds 36.2%, and hedge funds hold 19.4%.